Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer

Lung Cancer
24/07/2020

Zhongguo Fei Ai Za Zhi. 2020 Jul 20;23(7):609-614. doi: 10.3779/j.issn.1009-3419.2020.102.32.

ABSTRACT

Mesenchymal-epithelial transition factor (MET) gene is an important tumor driver gene of non-small cell lung cancer (NSCLC). Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabozantinib, savolitinib and tepotinib. The objective response rate of MET inhibitors is high, and the safety is good. However, resistance of MET-tyrosine kinase inhibitor (TKI) is inevitable, so it is


necessary to pay attention to the study of drug resistance mechanism. In addition, the combined use of hepatocyte growth factor (HGF)/MET inhibitors and other drugs may play an important role in inhibiting and reversing drug resistance.